Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Safety, Tolerability, Efficacy, and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for Treatment of Amyotrophic Lateral Sclerosis: Open-Label Extension

NCT03488524 is registered in ClinicalTrials.gov with Amylyx Pharmaceuticals Inc. as lead sponsor.

NCT NCT03488524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03488524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Safety, Tolerability, Efficacy, and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for Treatment of Amyotrophic Lateral Sclerosis: Open-Label Extension
Lead sponsor
Amylyx Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 29, 2018
Completion date
March 1, 2021
Enrollment
90 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

als, amyotrophic lateral sclerosis